Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-linea AB's gross profit for the
three
months ended in Jun. 2026 was kr2.55 Mil. Q-linea AB's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was kr2.59 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Q-linea AB's gross profit for the
three
months ended in Jun. 2026 was kr2.55 Mil. Q-linea AB's Revenue for the
three
months ended in Jun. 2026 was kr1.50 Mil. Therefore, Q-linea AB's Gross Margin % for the quarter that ended in Jun. 2026 was 169.80%.
Q-linea AB had a gross margin of 169.80% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 11 years, the highestGross Margin % of Q-linea AB was 26.31%. The lowest was -13176.54%. And the median was -538.91%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Q-linea AB had a gross margin of 169.80% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Q-linea AB Gross Profit Related Terms
Q-linea AB Gross Profit Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:QLINES vs ABT, SYK, MDT: Gross Profit Comparison
For the Medical Devices subindustry, Q-linea AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Gross Profit distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.59 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Q-linea AB (CHIX:QLINES) has a Gross Profit of kr2.59 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Q-linea AB and its competitors.
Is Q-linea AB's Gross Profit too high?
Q-linea AB's current Gross Profit is kr2.59 Mil. Overall, Q-linea AB has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Gross Profit compare to ABT and SYK?
Q-linea AB's Gross Profit of kr2.59 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Q-linea AB and its competitors. Q-linea AB's current Gross Profit is kr2.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Gross Profit of kr2.59 Mil. The stock's GF Value™ is kr1,776.96, compared to a current price of kr1,610.00 — trading 9.4% below its estimated fair value. The current Gross Profit is kr2.59 Mil. Q-linea AB's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Gross Profit is kr2.59 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 9.4% below its estimated GF Value™ of kr1,776.96.
Key valuation signals for CHIX:QLINES:
Gross Profit: kr2.59 Mil
GF Value™: kr1,776.96 vs. price of kr1,610.00 (9.4% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
66GF Score
Get the complete analysis for CHIX:QLINES
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
